Abstract:Background Toll-like receptors (TLRs) are important components of the innate and adaptive immune systems, and abnormal TLR expression has been linked to a variety of cancers. However, there was a lack of clarity on the association of TLR stimulation with the carcinogenesis of cancer. The study's goal was to analyse the clinical importance of TLRs expression at the mRNA level in pan-cancer datasets, as well as the link between TLR expression and carcinogenesis, progression, and clinical prognosis.Methods The expression profile of TLRs derived from UCSC pan-cancer data was analysed in multiple dimensions, including clinical analysis, immunological subtype analysis, tumour microenvironment (TME) analysis, tumour stem cell correlation analysis, and drug sensitivity analysis. Additionally, we analyse protein-protein interactions, functional enrichment, and chromatin accessibility, as well as TLR expression in single-cell sequencing data.Results Our multi-omics analysis results imply that TLRs may operate as a biological marker for carcinogenesis and progression, a potential target for anti-tumour therapy, and a prognostic biomarker, laying the theoretical groundwork for future translational medicine research.Conclusion TLRs are involved in the formation of malignancies and can be explored in further detail as potential prognostic indicators. Key MessagesToll-like receptors (TLRs) are key factors in the process of the innate and adaptive immune response, and their aberrant expression of TLRs have been widely reported in various cancer. However, the association between TLRs stimulation and tumorigenesis of cancer has not been well clarified.In this study, in the pan-cancer data, integrated TLR family gene expression analysis, clinical correlation analysis, immune subtype correlation analysis, tumour microenvironment correlation analysis, tumour stem cell correlation analysis, and drug sensitivity correlation analysis were performed.TLRs play an important role in the development of tumours and can be studied in depth as potential prognostic markers.

Advance in toll-like receptor 4 and tumor and its radiosensitivity

Toll-like Receptor 3 and Tumor Immunity

TLR4 Signaling Promotes Immune Escape of Human Lung Cancer Cells by Inducing Immunosuppressive Cytokines and Apoptosis Resistance.

TLR4 Enhances the Radiation Sensitivity of Tumor Cells

Toll-like Receptors Expressed in Tumor Cells: Targets for Therapy

Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells.

Knockdown Of Toll-Like Receptor 4 Inhibits Human Nsclc Cancer Cell Growth And Inflammatory Cytokine Secretion In Vitro And In Vivo

The Role of Toll-Like Receptor in Inflammation and Tumor Immunity

Small Interfering RNA-directed Targeting of Toll-like Receptor 4 Inhibits Human Prostate Cancer Cell Invasion, Survival, and Tumorigenicity.

Toll-like Receptor and Tumor Immunity

The Role of Toll-Like Receptors (tlrs) in Pan-Cancer

Toll-like Receptors and Tumor Immunology

Toll-Like Receptor 4 Prompts Human Breast Cancer Cells Invasiveness via Lipopolysaccharide Stimulation and Is Overexpressed in Patients with Lymph Node Metastasis

Toll-like receptor-targeted anti-tumor therapies: Advances and challenges

Toll-like Receptor 4 and Its Associated Proteins As Prognostic Factors for HCC Treated by Post-Radiotherapy Surgery.

MicroRNA and signal transduction pathways in tumor radiation response

The Role of Tumor Cells' TLRs in Promotion on Tumor and Their Mechanisms

Advances of study in affecting factors of tumor radiosensitivity

Relationship Between TLR4 and Inflammation-Related Cancers

Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells

TRAF4-mediated ubiquitination-dependent activation of JNK/Bcl-xL drives radioresistance